Loading clinical trials...
Loading clinical trials...
This study employs a modified continual reassessment method (mCRM) design to estimate the maximum tolerated dose (MTD) of PF-05230907, defined as a target toxicity rate of 15% based on treatment emerg...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Pfizer
NCT07458880 · Intracerebral Hemorrhage
NCT07455201 · Intracerebral Hemorrhage
NCT06725108 · Traumatic Brain Injury (TBI), Intracerebral Hemorrhage
NCT06797752 · OCTA, Severe Brain Injury, and more
NCT06219889 · Intracerebral Hemorrhage
Barnes Jewish Hospital
St Louis, Missouri
Washington University,
St Louis, Missouri
James Cancer Hospital and Solove Research Institute
Columbus, Ohio
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions